We are proud to share that Biocytogen is attending BIO-Europe from November 9th - 11th in Cologne, Germany. Labelled as “the new epicenter of biotech,” over 6,500 biopharma executives, investors, and industry partners will gather to discuss the strategic direction of the global life science industry. Visit us at booth #7-69 to discuss how we can support your next program—from antibody discovery with our AI-powered RenSupe Workstation to in vivo validation with our humanized BioMice models. Our integrated capabilities connect discovery with preclinical evidence to help advance promising therapeutics.
What is BIO-Europe?
BIO-Europe is the largest European partnering forum where attendees convene to address the increasingly complex biopharma landscape. This year’s conference includes an extended program to examine changing regulations, policies, and clinical developments. Packed with workshops, plenary sessions, presentations and networking receptions, discover the latest research findings and exciting collaboration opportunities.
Event Overview
Date: November 9th - 11th, 2026
Venue: Cologne Convention Center, Halls 7 & 8, Entrance North, Messeplatz 1, 50679 Cologne, Germany
Booth: 7 - 69
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
